Check out this new article which shows support for natural cancer treatments.  In healing from my skin cancer, melanoma, I checked out all the cancer support available naturally.  It has widely been used for years oxygen based products.  Cancer can’t survive in an oxygenated environment.  This a crucial step in your cancer journey.

Now pharmiceuticals are coming on board.  Again not a natural way, but they see cancer tissues are low in oxygen.

Introduction Of Oxygen-Based Product To Davanat With 5-FU To Treat All Solid Tumors, Especially Head & Neck, Breast
Business Wire

July 15, 2008

NEWTON, Mass. — Pro-Pharmaceuticals, Inc., a biopharmaceutical company developing proprietary polysaccharide-based therapeutic compounds in the treatment of cancer and fibrosis, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (“FDA”) to define the regimen for an Oxygen-based product (EZ-646) to be used with Galactomannan-C (DAVANAT(R)) and Fluorouracil (5-FU) to treat all solid tumors, including new indications such as head & neck and breast cancers. The proposed meeting agenda is in direct response to current promising studies regarding the relationship between solid tumor attenuation and hypoxia.

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

Many human tumors contain a significant fraction of hypoxic cells, due to uncontrolled cell growth and insufficient vascularization. Oxygen measurements of several cancer types show a range of oxygen in the tumor tissues, which is significantly lower than the adjacent normal tissues. The reduction in oxygen within tumors confers resistance to both radiotherapy and chemotherapy, and in many cases correlates with a poor prognosis.

On May 16, 2008, the company submitted a drug master file application (Type II DMF No. 21629) as an important step in its planned New Drug Application (NDA) filing to the FDA for the company’s lead drug candidate, DAVANAT(R). Based on the completion of final reports of Phase I and Phase II clinical trials (IND serials 0032 and 0051, September 22, 2006 and February 2, 2008, respectively) for all solid tumors and colorectal cancer, published research, safety data, and new in vitro studies, the company finds the results compelling and is exploring the promise of this new combination therapy in addition to DAVANAT(R) with 5-FU.

“Oxygen therapy has been explored over the years but the underlying implications are very exciting,” said Eliezer Zomer, Ph.D., Executive Vice President Product Development & Manufacturing. “The current published data lends itself to what we believe to be evolutionary in the field of solid tumor reduction.”

David Platt, Ph.D., Chairman and CEO of Pro-Pharmaceuticals, commented, “We strongly believe the addition of EZ-646 can help increase efficacy. There is much data supporting this move and we believe the FDA will encourage our efforts.”